VSTM Verastem, Inc.

NASDAQ
$7.90

Verastem, Inc. (VSTM) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +18.8% since its last earnings release on August 6, 2026.

Verastem Beat Consensus Estimates
Thursday, August 6, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.44)
Rev est $28.45M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.53

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Verastem, Inc.

Verastem Inc is a biopharmaceutical company engaged in discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.